首页 > 最新文献

Revista De Investigacion Clinica-Clinical and Translational Investigation最新文献

英文 中文
Association of Smoking with Disease Progression in Persons with Multiple Sclerosis Undergoing Autologous Hematopoietic Cell Transplantation: A Single-Center Experience. 接受自体造血细胞移植的多发性硬化症患者吸烟与疾病进展的关系:单中心经验
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.24875/RIC.24000203
Fernández-Lara Danitza, Porcel José M, Robles-Hernández Robinson, Lira-Lara Olivia, Melgar-de-la-Paz Miranda, Gallardo-Pérez Moisés Manuel, Olivares-Gazca Juan C, Ruiz-Delgado Guillermo J, Ruiz-Argüelles Guillermo J

Unassigned: Background: Smoking remains a significant issue that increases the prevalence of multiple sclerosis (MS) and its progression to secondary progressive forms. Objectives: The goal is to identify the relationship between smoking and disease progression in MS patients who have undergone autologous hematopoietic stem cell transplantation (auto-HSCT) at the Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, Mexico. Methods: This retrospective study involved MS patients treated with auto-HSCT, followed for 12 months. The response to transplantation was measured using the difference in Expanded Disability Status Scale (EDSS) scores before and 12 months after the transplant. A difference of -0.5 or greater indicated a good response, while a difference below 0.5 indicated a poor response. Results: The study included 419 patients, with a median age of 47 years (IQR: 40-53). The majority were non-smokers (315) compared to smokers/ex-smokers (104). In patients with PMSS, EDSS stabilization at 12 months was observed in both smokers/ex-smokers (median 6, interquartile range (IQR) = 1 vs. 6, IQR = 1, p = 0.466) and non-smokers (median 6, IQR = 1 vs. 6, IQR = 1.5, p = 0.001), although non-smokers showed a statistically significant difference. Conclusion: Smoking may negatively impact MS progression, especially in its progressive forms. (Rev Invest Clin. 2024;76(5):223-9).

未分配:背景:吸烟仍然是一个重要问题,它会增加多发性硬化症(MS)的发病率,并使其发展为继发性进展。研究目的目的:在墨西哥普埃布拉鲁伊斯诊所血液学与国际医学中心(Centro de Hematología y Medicina Interna)接受自体造血干细胞移植(auto-HSCT)的多发性硬化症患者中,确定吸烟与疾病进展之间的关系。方法:这项回顾性研究涉及接受自体供体移植治疗的多发性硬化症患者,随访时间为 12 个月。移植后的反应通过移植前和移植后12个月的扩展残疾状态量表(EDSS)评分差异来衡量。差值在-0.5或以上表示反应良好,差值在0.5以下表示反应不佳。研究结果研究共纳入 419 名患者,中位年龄为 47 岁(IQR:40-53)。大多数患者为非吸烟者(315 人),而吸烟者/戒烟者为 104 人。在 PMSS 患者中,吸烟者/戒烟者(中位数 6,四分位数间距 (IQR) = 1 vs. 6,IQR = 1,p = 0.466)和非吸烟者(中位数 6,四分位数间距 (IQR) = 1 vs. 6,IQR = 1.5,p = 0.001)的 EDSS 在 12 个月后均趋于稳定,但非吸烟者之间的差异具有统计学意义。结论吸烟可能对多发性硬化症的进展产生负面影响,尤其是进展期多发性硬化症。(Rev Invest Clin.2024;76(5):223-9).
{"title":"Association of Smoking with Disease Progression in Persons with Multiple Sclerosis Undergoing Autologous Hematopoietic Cell Transplantation: A Single-Center Experience.","authors":"Fernández-Lara Danitza, Porcel José M, Robles-Hernández Robinson, Lira-Lara Olivia, Melgar-de-la-Paz Miranda, Gallardo-Pérez Moisés Manuel, Olivares-Gazca Juan C, Ruiz-Delgado Guillermo J, Ruiz-Argüelles Guillermo J","doi":"10.24875/RIC.24000203","DOIUrl":"10.24875/RIC.24000203","url":null,"abstract":"<p><strong>Unassigned: </strong>Background: Smoking remains a significant issue that increases the prevalence of multiple sclerosis (MS) and its progression to secondary progressive forms. Objectives: The goal is to identify the relationship between smoking and disease progression in MS patients who have undergone autologous hematopoietic stem cell transplantation (auto-HSCT) at the Centro de Hematología y Medicina Interna, Clínica Ruiz, Puebla, Mexico. Methods: This retrospective study involved MS patients treated with auto-HSCT, followed for 12 months. The response to transplantation was measured using the difference in Expanded Disability Status Scale (EDSS) scores before and 12 months after the transplant. A difference of -0.5 or greater indicated a good response, while a difference below 0.5 indicated a poor response. Results: The study included 419 patients, with a median age of 47 years (IQR: 40-53). The majority were non-smokers (315) compared to smokers/ex-smokers (104). In patients with PMSS, EDSS stabilization at 12 months was observed in both smokers/ex-smokers (median 6, interquartile range (IQR) = 1 vs. 6, IQR = 1, p = 0.466) and non-smokers (median 6, IQR = 1 vs. 6, IQR = 1.5, p = 0.001), although non-smokers showed a statistically significant difference. Conclusion: Smoking may negatively impact MS progression, especially in its progressive forms. (Rev Invest Clin. 2024;76(5):223-9).</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 5","pages":"223-229"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142631416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The rs1477196 SNP of the FTO Gene is Associated with Primary Knee Osteoarthritis in a Female Population from Northern Mexico. 在墨西哥北部的一个女性群体中,FTO 基因的 rs1477196 SNP 与原发性膝骨关节炎有关。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.24875/RIC.23000259
Rubén D Arellano-Pérez-Vertti, Faviel F González-Galarza, Denisse Prone-Olazábal, Daniel O Arellano-Ramírez, Diego F Arellano-Ramírez, Cristina S Argüello-Beltrán, Michelle A Tovar-Aguilar, Mónica Berúmen-Rodríguez, Adria I Prieto-Hinojosa, Alejandra Méndez-Hernández, Rafael Argüello-Astorga

Background: Osteoarthritis is a frequent rheumatic disease. Some single-nucleotide polymorphisms of the gene associated with fat mass and obesity are associated with increased body mass index and knee osteoarthritis.

Objective: The objective of this study was to analyze the association of single nucleotide polymorphism rs1477196 of the fat mass and obesity gene with primary knee osteoarthritis.

Methods: This observational and cross-sectional study included 347 Mexican participants. We performed the genotypification analysis with TaqMan® probe C_2031262_10 for rs1477196 (Thermo Fisher Scientific). Multivariate analysis included covariables such as age, type 2 diabetes, obesity, and postmenopause.

Results: Type 2 diabetes, obesity, and postmenopause were associated with primary knee osteoarthritis in female participants. We did not find an association between rs1477196 and obesity. In the codominant and dominant genetic models, rs1477196 was significantly associated with primary knee osteoarthritis only in the female group, including in the model adjusted by other covariables (odds ratio = 2.517; 1.035-6.123; p = 0.042 and odds ratio = 2.387; 1.054-5.407; p = 0.037, respectively). The interaction between rs1477196 and obesity was significantly associated with primary knee osteoarthritis in female participants (p = 0.039 and p = 0.043).

Conclusions: Our findings suggest that the rs1477196 variant of the fat and obesity mass gene may be associated with the risk of primary knee osteoarthritis in women.

未分配:背景:骨关节炎是一种常见的风湿性疾病。一些与脂肪量和肥胖有关的单核苷酸多态性基因与体重指数增加和膝骨关节炎有关。研究目的本研究旨在分析脂肪量和肥胖基因的单核苷酸多态性 rs1477196 与原发性膝骨关节炎的相关性。研究方法这项观察性横断面研究纳入了 347 名墨西哥参与者。我们使用 TaqMan® 探针 C_2031262_10 对 rs1477196 (赛默飞世尔科技公司)进行了基因分型分析。多变量分析包括年龄、2 型糖尿病、肥胖和绝经后等协变量。结果2型糖尿病、肥胖和绝经后与女性参与者的原发性膝骨关节炎有关。我们没有发现 rs1477196 与肥胖有关。在共显性和显性遗传模型中,rs1477196 仅与女性组的原发性膝骨关节炎显著相关,包括在经其他协变量调整的模型中(几率比分别为 2.517; 1.035-6.123; p = 0.042 和几率比分别为 2.387; 1.054-5.407; p = 0.037)。在女性参与者中,rs1477196与肥胖之间的交互作用与原发性膝骨关节炎显著相关(p = 0.039 和 p = 0.043)。结论我们的研究结果表明,脂肪和肥胖质量基因的 rs1477196 变体可能与女性原发性膝骨关节炎的风险有关。(Rev invest clin.2024;76(1):37-44).
{"title":"The rs1477196 SNP of the FTO Gene is Associated with Primary Knee Osteoarthritis in a Female Population from Northern Mexico.","authors":"Rubén D Arellano-Pérez-Vertti, Faviel F González-Galarza, Denisse Prone-Olazábal, Daniel O Arellano-Ramírez, Diego F Arellano-Ramírez, Cristina S Argüello-Beltrán, Michelle A Tovar-Aguilar, Mónica Berúmen-Rodríguez, Adria I Prieto-Hinojosa, Alejandra Méndez-Hernández, Rafael Argüello-Astorga","doi":"10.24875/RIC.23000259","DOIUrl":"10.24875/RIC.23000259","url":null,"abstract":"<p><strong>Background: </strong>Osteoarthritis is a frequent rheumatic disease. Some single-nucleotide polymorphisms of the gene associated with fat mass and obesity are associated with increased body mass index and knee osteoarthritis.</p><p><strong>Objective: </strong>The objective of this study was to analyze the association of single nucleotide polymorphism rs1477196 of the fat mass and obesity gene with primary knee osteoarthritis.</p><p><strong>Methods: </strong>This observational and cross-sectional study included 347 Mexican participants. We performed the genotypification analysis with TaqMan® probe C_2031262_10 for rs1477196 (Thermo Fisher Scientific). Multivariate analysis included covariables such as age, type 2 diabetes, obesity, and postmenopause.</p><p><strong>Results: </strong>Type 2 diabetes, obesity, and postmenopause were associated with primary knee osteoarthritis in female participants. We did not find an association between rs1477196 and obesity. In the codominant and dominant genetic models, rs1477196 was significantly associated with primary knee osteoarthritis only in the female group, including in the model adjusted by other covariables (odds ratio = 2.517; 1.035-6.123; p = 0.042 and odds ratio = 2.387; 1.054-5.407; p = 0.037, respectively). The interaction between rs1477196 and obesity was significantly associated with primary knee osteoarthritis in female participants (p = 0.039 and p = 0.043).</p><p><strong>Conclusions: </strong>Our findings suggest that the rs1477196 variant of the fat and obesity mass gene may be associated with the risk of primary knee osteoarthritis in women.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 1","pages":"37-44"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140040720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Agreement between Cerebrospinal Fluid Biomarkers, Brain 18-Fluorodeoxyglucose PET, and Clinical Diagnosis in Older Adults with Cognitive Impairment. 有认知障碍的老年人脑脊液生物标记物、脑18-氟脱氧葡萄糖PET与临床诊断之间的一致性
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.24875/RIC.24000161
Mimenza-Alvarado Alberto J, León-Del-Ángel Karen G, Hernández-Ramírez Rodrigo, Rodríguez-Callejas Juan de D, Yeverino-Castro Sara G, Aguilar-Navarro Sara G

Unassigned: Background: Clinical practice has advanced toward a combined diagnostic approach that involves clinical criteria and biological markers for Alzheimer's disease (AD) and other dementias. Objective: To establish the level of diagnostic agreement between an initial clinical diagnosis and cerebrospinal fluid (CSF) and [18F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) biomarkers in a cohort of patients from a memory clinic. Methods: This is a observational, retrospective, cohort study conducted at an outpatient memory clinic. Between July 2018 and September 2023, data from adults' ≥ 55 years with a mild cognitive impairment or dementia diagnosis without etiological diagnosis were obtained, complemented with the evaluation of biomarkers in CSF and [18F] FDG-PET biomarker assessment were included. Kappa coefficients (κ) were used to establish the level of agreement between CSF and [18F] FDG-PET results. Results: Seventy-seven patients had an available [18F] FDG-PET scan, and 25 (32.5%) had both biomarkers. We observed a fair-to-moderate diagnostic agreement between patients' initial and their final diagnosis in the presence of CSF (κ = 0.233, 95% confidence interval [CI]: -0.099-0.566) and [18F] FDG-PET (κ = 0.451, 95% CI: 0.277-0.625, p < 0.001) results. The Kappa value for diagnostic concordance between [18F] FDG-PET and CSF to differentiate between AD and other dementias was 0.733 (95% CI: 0.425-1.000, p < 0.005). Conclusion: This study demonstrates good agreement between the CSF and FDG-PET biomarkers to differentiate AD from other dementias. (Rev Invest Clin. 2024;76(5):230-7).

未分配:背景:临床实践中,阿尔茨海默病(AD)和其他痴呆症的临床标准与生物标志物相结合的诊断方法已取得进展。目的在记忆诊所的一组患者中确定初步临床诊断与脑脊液(CSF)和[18F]-氟脱氧葡萄糖(FDG)-正电子发射断层扫描(PET)生物标记物之间的诊断一致性水平。方法:这是一项在记忆门诊进行的观察性、回顾性队列研究。在 2018 年 7 月至 2023 年 9 月期间,获得了年龄≥ 55 岁、有轻度认知障碍或痴呆诊断但无病因诊断的成年人的数据,并对 CSF 中的生物标志物进行了评估,同时纳入了[18F] FDG-PET 生物标志物评估。卡帕系数(κ)用于确定脑脊液和[18F] FDG-PET结果之间的一致程度。结果77名患者接受了[18F] FDG-PET扫描,其中25名患者(32.5%)同时接受了两种生物标记物的扫描。我们观察到,在 CSF(κ = 0.233,95% 置信区间 [CI]:-0.099-0.566)和 [18F] FDG-PET (κ = 0.451,95% 置信区间 [CI]:0.277-0.625,p < 0.001)结果存在的情况下,患者的初步诊断与最终诊断之间存在相当到中等程度的诊断一致性。[18F]FDG-PET和CSF在区分AD和其他痴呆症方面的诊断一致性Kappa值为0.733(95% CI:0.425-1.000,p <0.005)。结论本研究表明,CSF 和 FDG-PET 生物标记物在区分 AD 和其他痴呆症方面具有良好的一致性。(Rev Invest Clin.2024;76(5):230-7).
{"title":"Agreement between Cerebrospinal Fluid Biomarkers, Brain 18-Fluorodeoxyglucose PET, and Clinical Diagnosis in Older Adults with Cognitive Impairment.","authors":"Mimenza-Alvarado Alberto J, León-Del-Ángel Karen G, Hernández-Ramírez Rodrigo, Rodríguez-Callejas Juan de D, Yeverino-Castro Sara G, Aguilar-Navarro Sara G","doi":"10.24875/RIC.24000161","DOIUrl":"10.24875/RIC.24000161","url":null,"abstract":"<p><strong>Unassigned: </strong>Background: Clinical practice has advanced toward a combined diagnostic approach that involves clinical criteria and biological markers for Alzheimer's disease (AD) and other dementias. Objective: To establish the level of diagnostic agreement between an initial clinical diagnosis and cerebrospinal fluid (CSF) and [18F]-fluorodeoxyglucose (FDG)-positron emission tomography (PET) biomarkers in a cohort of patients from a memory clinic. Methods: This is a observational, retrospective, cohort study conducted at an outpatient memory clinic. Between July 2018 and September 2023, data from adults' ≥ 55 years with a mild cognitive impairment or dementia diagnosis without etiological diagnosis were obtained, complemented with the evaluation of biomarkers in CSF and [18F] FDG-PET biomarker assessment were included. Kappa coefficients (κ) were used to establish the level of agreement between CSF and [18F] FDG-PET results. Results: Seventy-seven patients had an available [18F] FDG-PET scan, and 25 (32.5%) had both biomarkers. We observed a fair-to-moderate diagnostic agreement between patients' initial and their final diagnosis in the presence of CSF (κ = 0.233, 95% confidence interval [CI]: -0.099-0.566) and [18F] FDG-PET (κ = 0.451, 95% CI: 0.277-0.625, p < 0.001) results. The Kappa value for diagnostic concordance between [18F] FDG-PET and CSF to differentiate between AD and other dementias was 0.733 (95% CI: 0.425-1.000, p < 0.005). Conclusion: This study demonstrates good agreement between the CSF and FDG-PET biomarkers to differentiate AD from other dementias. (Rev Invest Clin. 2024;76(5):230-7).</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 5","pages":"230-237"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142631303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction of Prognostic Features Based on Neutrophil-Related Genes for Lung Squamous Cell Carcinoma Reveals Immune Landscape and Drug Candidates. 基于中性粒细胞相关基因的肺鳞癌预后特征预测揭示了免疫格局和候选药物
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.24875/RIC.23000262
Du Sili, Zhang Nan

Unassigned: Background: Since to the prognosis of lung squamous cell carcinoma is generally poor, there is an urgent need to innovate new prognostic biomarkers and therapeutic targets to improve patient outcomes. Objectives: Our goal was to develop a novel multi-gene prognostic model linked to neutrophils for predicting lung squamous cell carcinoma prognosis. Methods: We utilized messenger RNA expression profiles and relevant clinical data of lung squamous cell carcinoma patients from the Cancer Genome Atlas database. Through K-means clustering, least absolute shrinkage and selection operator regression, and univariate/multivariate Cox regression analyses, we identified 12 neutrophil-related genes strongly related to patient survival and constructed a prognostic model. We verified the stability of the model in the Cancer Genome Atlas database and gene expression omnibus validation set, demonstrating the robust predictive performance of the model. Results: Immunoinfiltration analysis revealed remarkably elevated levels of infiltration for natural killer cells resting and monocytes in the high-risk group compared to the low-risk group, while macrophages had considerably lower infiltration in the high risk group. Most immune checkpoint genes, including programmed cell death protein 1 and cytotoxic T-lymphocyte-associated antigen 4, exhibited high expression levels in the high risk group. Tumor immune dysfunction and exclusion scores and immunophenoscore results suggested a potential inclination toward immunotherapy in the "RIC" version V2 revised high risk group. Moreover, prediction results from the CellMiner database revealed great correlations between drug sensitivity (e.g., Vinorelbine and PKI-587) and prognostic genes. Conclusion: Overall, our study established a reliable prognostic risk model that possessed significant value in predicting the overall survival of lung squamous cell carcinoma patients and may guide personalized treatment strategies. (Rev Invest Clin. 2024;76(2):116-31).

未分配:背景:由于肺鳞状细胞癌的预后普遍较差,因此迫切需要创新新的预后生物标志物和治疗靶点,以改善患者的预后。研究目标我们的目标是开发一种与中性粒细胞相关的新型多基因预后模型,用于预测肺鳞癌的预后。方法我们利用癌症基因组图谱数据库中肺鳞状细胞癌患者的信使 RNA 表达谱和相关临床数据。通过 K-均值聚类、最小绝对收缩和选择算子回归以及单变量/多变量 Cox 回归分析,我们确定了与患者生存密切相关的 12 个中性粒细胞相关基因,并构建了一个预后模型。我们在癌症基因组图谱数据库和基因表达总括验证集中验证了该模型的稳定性,证明了该模型稳健的预测性能。结果免疫浸润分析表明,与低风险组相比,高风险组的自然杀伤细胞和单核细胞浸润水平明显升高,而巨噬细胞在高风险组的浸润水平要低得多。大多数免疫检查点基因,包括程序性细胞死亡蛋白1和细胞毒性T淋巴细胞相关抗原4,在高风险组中都表现出较高的表达水平。肿瘤免疫功能障碍和排斥评分以及免疫表观评分结果表明,"RIC "版 V2 修订版高风险组可能倾向于免疫疗法。此外,CellMiner 数据库的预测结果显示,药物敏感性(如长春瑞滨和 PKI-587)与预后基因之间存在很大的相关性。结论总之,我们的研究建立了一个可靠的预后风险模型,该模型在预测肺鳞癌患者的总体生存期方面具有重要价值,并可指导个性化治疗策略。(Rev Invest Clin.2024;76(2):116-31).
{"title":"Prediction of Prognostic Features Based on Neutrophil-Related Genes for Lung Squamous Cell Carcinoma Reveals Immune Landscape and Drug Candidates.","authors":"Du Sili, Zhang Nan","doi":"10.24875/RIC.23000262","DOIUrl":"https://doi.org/10.24875/RIC.23000262","url":null,"abstract":"<p><strong>Unassigned: </strong>Background: Since to the prognosis of lung squamous cell carcinoma is generally poor, there is an urgent need to innovate new prognostic biomarkers and therapeutic targets to improve patient outcomes. Objectives: Our goal was to develop a novel multi-gene prognostic model linked to neutrophils for predicting lung squamous cell carcinoma prognosis. Methods: We utilized messenger RNA expression profiles and relevant clinical data of lung squamous cell carcinoma patients from the Cancer Genome Atlas database. Through K-means clustering, least absolute shrinkage and selection operator regression, and univariate/multivariate Cox regression analyses, we identified 12 neutrophil-related genes strongly related to patient survival and constructed a prognostic model. We verified the stability of the model in the Cancer Genome Atlas database and gene expression omnibus validation set, demonstrating the robust predictive performance of the model. Results: Immunoinfiltration analysis revealed remarkably elevated levels of infiltration for natural killer cells resting and monocytes in the high-risk group compared to the low-risk group, while macrophages had considerably lower infiltration in the high risk group. Most immune checkpoint genes, including programmed cell death protein 1 and cytotoxic T-lymphocyte-associated antigen 4, exhibited high expression levels in the high risk group. Tumor immune dysfunction and exclusion scores and immunophenoscore results suggested a potential inclination toward immunotherapy in the \"RIC\" version V2 revised high risk group. Moreover, prediction results from the CellMiner database revealed great correlations between drug sensitivity (e.g., Vinorelbine and PKI-587) and prognostic genes. Conclusion: Overall, our study established a reliable prognostic risk model that possessed significant value in predicting the overall survival of lung squamous cell carcinoma patients and may guide personalized treatment strategies. (Rev Invest Clin. 2024;76(2):116-31).</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 2","pages":"116-131"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140917276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Longitudinal Trends in HIV-1 Subtypes and Drug Resistance in Children from Argentina over a 15-Year Period (2006-2021). 阿根廷儿童 15 年间(2006-2021 年)HIV-1 亚型和耐药性的纵向趋势。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.24875/RIC.23000210
Natalia J López, Solange Arazi-Caillaud, Rosa M Bologna, Andrea M Mangano, Paula C Aulicino

Background: Human immunodeficiency virus (HIV) drug resistance is a major cause of treatment failure in children and adolescents infected with the virus.

Objectives: The objectives of the study are to investigate HIV drug resistance (HIVDR) in patients who attended a referral care center in Argentina over a 15-year period and to compare mutational patterns between HIV-1 polsequences characterized as B or BF recombinants.

Methods: Individual resistance-associated mutations (RAMs) (to protease and reverse transcriptase inhibitors) were identified according to IAS-USA guidelines in 374 HIV-1-infected children and adolescents. HIV-1 subtype was characterized by phylogenetic and recombination analysis using MEGA5.1 and Simplot. Poisson linear regression was used to model the dynamics of the RAMs over time.

Results: The prevalence of RAMs to protease inhibitors (R2 = 0.52, p = 0.0012) and nucleoside reverse transcriptase inhibitors (R2 = 0.30, p = 0.0225) decreased over time. HIVDR to non-nucleoside reverse transcriptase inhibitors remained moderate to high, ranging between 33% and 76%. BF recombinants showed a higher frequency of thymidine analog mutation 1 RAMs profile and I54V mutation.

Conclusion: In Argentina, HIVDR observed in children and adolescents has decreased over the past 15 years, regardless of the viral subtype. (REV INVEST CLIN. 2024;76(1):29-36).

未分配:背景:人类免疫缺陷病毒(HIV)耐药性是感染该病毒的儿童和青少年治疗失败的主要原因。研究目的本研究的目的是调查阿根廷一家转诊护理中心 15 年间就诊患者的 HIV 耐药性(HIVDR),并比较被定性为 B 型或 BF 型重组病毒的 HIV-1 多序列之间的变异模式。方法根据 IAS-USA 指南,在 374 名感染 HIV-1 的儿童和青少年中确定了单个耐药性相关突变(RAM)(对蛋白酶和逆转录酶抑制剂)。通过使用 MEGA5.1 和 Simplot 进行系统发育和重组分析,确定了 HIV-1 亚型的特征。泊松线性回归用于模拟 RAMs 随时间变化的动态变化。结果显示蛋白酶抑制剂(R2 = 0.52,p = 0.0012)和核苷酸逆转录酶抑制剂(R2 = 0.30,p = 0.0225)的 RAM 流行率随时间推移而下降。对非核苷类逆转录酶抑制剂的 HIVDR 仍保持在中高水平,介于 33% 与 76% 之间。BF 重组株出现胸苷类似物突变 1 RAMs 特征和 I54V 突变的频率较高。结论在阿根廷,无论病毒亚型如何,过去 15 年中在儿童和青少年中观察到的 HIVDR 均有所下降。(Rev invest clin.2024;76(1):29-36).
{"title":"Longitudinal Trends in HIV-1 Subtypes and Drug Resistance in Children from Argentina over a 15-Year Period (2006-2021).","authors":"Natalia J López, Solange Arazi-Caillaud, Rosa M Bologna, Andrea M Mangano, Paula C Aulicino","doi":"10.24875/RIC.23000210","DOIUrl":"10.24875/RIC.23000210","url":null,"abstract":"<p><strong>Background: </strong>Human immunodeficiency virus (HIV) drug resistance is a major cause of treatment failure in children and adolescents infected with the virus.</p><p><strong>Objectives: </strong>The objectives of the study are to investigate HIV drug resistance (HIVDR) in patients who attended a referral care center in Argentina over a 15-year period and to compare mutational patterns between HIV-1 polsequences characterized as B or BF recombinants.</p><p><strong>Methods: </strong>Individual resistance-associated mutations (RAMs) (to protease and reverse transcriptase inhibitors) were identified according to IAS-USA guidelines in 374 HIV-1-infected children and adolescents. HIV-1 subtype was characterized by phylogenetic and recombination analysis using MEGA5.1 and Simplot. Poisson linear regression was used to model the dynamics of the RAMs over time.</p><p><strong>Results: </strong>The prevalence of RAMs to protease inhibitors (R2 = 0.52, p = 0.0012) and nucleoside reverse transcriptase inhibitors (R2 = 0.30, p = 0.0225) decreased over time. HIVDR to non-nucleoside reverse transcriptase inhibitors remained moderate to high, ranging between 33% and 76%. BF recombinants showed a higher frequency of thymidine analog mutation 1 RAMs profile and I54V mutation.</p><p><strong>Conclusion: </strong>In Argentina, HIVDR observed in children and adolescents has decreased over the past 15 years, regardless of the viral subtype. (REV INVEST CLIN. 2024;76(1):29-36).</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 1","pages":"29-36"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140040760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling. PKMYT1 通过激活 Notch 信号促进三阴性乳腺癌的上皮-间质转化过程
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2024-01-01 DOI: 10.24875/RIC.23000256
Bin Li, Lin Huang, Jian Ruan

Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer (BC) that lacks receptors for targeted therapy. Deeper insight into the molecular mechanisms regulating TNBC metastasis is urgently needed. The epithelial-mesenchymal transition process facilitates the metastasis of neighboring epithelial tumor cells. Protein kinase, membrane-associated tyrosine/threonine 1 (PKMYT1), a member of the Wee family of protein kinases, is upregulated in BC, and its high expression predicts poor prognosis in BC patients. Notch signaling activation is a pathognomonic feature of TNBC. PKMYT1 has been found to induce EMT in non-small cell lung cancer by activating Notch signaling. However, whether PKMYT1 exerts effects on TNBC progression by regulating Notch signaling remains unknown.

Objectives: The objective of this study was to investigate whether PKMYT1 exerts effects on TNBC progression by regulating Notch signaling.

Methods: Fifty cases of surgically resected BC samples (tumor and adjacent non-tumor tissue samples) were collected from patients diagnosed with BC. We measured the expression of PKMYT1 in clinical samples with real-time quantitative polymerase chain reaction (RT-qPCR). For in vitro analysis, RT-qPCR and Western blotting were conducted to evaluate PKMYT1 expression in TNBC cells. Then, the viability, migration, and invasion of TNBC cells were detected by cell counting kit-8 assays, wound healing assays, and Transwell assays. The EMT event was examined by evaluating the levels of EMT-associated proteins. For in vivo analysis, xenograft models in nude mice were established to explore PKMYT1 roles. E-cadherin and Ki67 expression in xenograft models were estimated by immunohistochemistry staining. Hematoxylin and eosin staining was performed to assess tumor metastasis. The underlying mechanisms by which PKMYT1 affected the malignant phenotypes of TNBC cells were explored by Western blotting measuring the pathway-associated proteins.

Results: PKMYT1 was upregulated in BC tissues and cells, and its knockdown prevented cell proliferation, migration, invasion, and EMT event in TNBC. Mechanistically, Notch signaling was inactivated by PKMYT1 depletion, and Notch activation abolished the PKMYT1 silencing-induced inhibition in the malignant phenotypes of TNBC cells. For in vivo analysis, PKMYT1 knockdown inhibited tumorigenesis and metastasis of TNBC.

Conclusion: PKMYT1 promotes EMT, proliferation, migration, and invasion of TNBC cells and facilitates tumor growth and metastasis by activating Notch signaling.

未分配:背景:三阴性乳腺癌(TNBC)是乳腺癌(BC)的一种亚型,缺乏靶向治疗受体。目前迫切需要深入了解调控 TNBC 转移的分子机制。上皮-间质转化过程促进了邻近上皮肿瘤细胞的转移。蛋白激酶,膜相关酪氨酸/苏氨酸1(PKMYT1)是Wee蛋白激酶家族的成员,在BC中上调,其高表达预示着BC患者的不良预后。Notch信号激活是TNBC的标志性特征。研究发现,PKMYT1可通过激活Notch信号诱导非小细胞肺癌的EMT。然而,PKMYT1是否通过调节Notch信号转导对TNBC的进展产生影响仍是未知数。研究目的本研究旨在探讨 PKMYT1 是否通过调节 Notch 信号对 TNBC 的进展产生影响。研究方法从确诊为BC的患者中收集50例手术切除的BC样本(肿瘤和邻近的非肿瘤组织样本)。我们用实时定量聚合酶链反应(RT-qPCR)测定了临床样本中 PKMYT1 的表达。在体外分析中,我们采用 RT-qPCR 和 Western 印迹技术评估 PKMYT1 在 TNBC 细胞中的表达。然后,通过细胞计数试剂盒-8测定法、伤口愈合测定法和Transwell测定法检测TNBC细胞的活力、迁移和侵袭。通过评估 EMT 相关蛋白的水平来检测 EMT 事件。在体内分析方面,建立了裸鼠异种移植模型,以探索 PKMYT1 的作用。异种移植模型中E-cadherin和Ki67的表达通过免疫组化染色法进行评估。血红素和伊红染色用于评估肿瘤转移情况。通过Western印迹检测通路相关蛋白,探讨了PKMYT1影响TNBC细胞恶性表型的内在机制。结果发现PKMYT1在BC组织和细胞中上调,其敲除可阻止TNBC的细胞增殖、迁移、侵袭和EMT事件。从机理上讲,PKMYT1被敲除后,Notch信号转导失活,Notch激活后,PKMYT1沉默诱导的TNBC细胞恶性表型抑制作用消失。在体内分析中,PKMYT1敲除抑制了TNBC的肿瘤发生和转移。结论PKMYT1能促进TNBC细胞的EMT、增殖、迁移和侵袭,并通过激活Notch信号促进肿瘤生长和转移。(Rev invest clin.2024;76(1):45-59).
{"title":"PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling.","authors":"Bin Li, Lin Huang, Jian Ruan","doi":"10.24875/RIC.23000256","DOIUrl":"10.24875/RIC.23000256","url":null,"abstract":"<p><strong>Background: </strong>Triple-negative breast cancer (TNBC) is a subtype of breast cancer (BC) that lacks receptors for targeted therapy. Deeper insight into the molecular mechanisms regulating TNBC metastasis is urgently needed. The epithelial-mesenchymal transition process facilitates the metastasis of neighboring epithelial tumor cells. Protein kinase, membrane-associated tyrosine/threonine 1 (PKMYT1), a member of the Wee family of protein kinases, is upregulated in BC, and its high expression predicts poor prognosis in BC patients. Notch signaling activation is a pathognomonic feature of TNBC. PKMYT1 has been found to induce EMT in non-small cell lung cancer by activating Notch signaling. However, whether PKMYT1 exerts effects on TNBC progression by regulating Notch signaling remains unknown.</p><p><strong>Objectives: </strong>The objective of this study was to investigate whether PKMYT1 exerts effects on TNBC progression by regulating Notch signaling.</p><p><strong>Methods: </strong>Fifty cases of surgically resected BC samples (tumor and adjacent non-tumor tissue samples) were collected from patients diagnosed with BC. We measured the expression of PKMYT1 in clinical samples with real-time quantitative polymerase chain reaction (RT-qPCR). For in vitro analysis, RT-qPCR and Western blotting were conducted to evaluate PKMYT1 expression in TNBC cells. Then, the viability, migration, and invasion of TNBC cells were detected by cell counting kit-8 assays, wound healing assays, and Transwell assays. The EMT event was examined by evaluating the levels of EMT-associated proteins. For in vivo analysis, xenograft models in nude mice were established to explore PKMYT1 roles. E-cadherin and Ki67 expression in xenograft models were estimated by immunohistochemistry staining. Hematoxylin and eosin staining was performed to assess tumor metastasis. The underlying mechanisms by which PKMYT1 affected the malignant phenotypes of TNBC cells were explored by Western blotting measuring the pathway-associated proteins.</p><p><strong>Results: </strong>PKMYT1 was upregulated in BC tissues and cells, and its knockdown prevented cell proliferation, migration, invasion, and EMT event in TNBC. Mechanistically, Notch signaling was inactivated by PKMYT1 depletion, and Notch activation abolished the PKMYT1 silencing-induced inhibition in the malignant phenotypes of TNBC cells. For in vivo analysis, PKMYT1 knockdown inhibited tumorigenesis and metastasis of TNBC.</p><p><strong>Conclusion: </strong>PKMYT1 promotes EMT, proliferation, migration, and invasion of TNBC cells and facilitates tumor growth and metastasis by activating Notch signaling.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 1","pages":"45-59"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140040719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Are medium cut-off membranes the future, or the promising reality for chronic hemodialysis patients? 对于慢性血液透析患者来说,中切断膜是未来,还是有希望的现实?
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2023-12-18 DOI: 10.24875/RIC.23000213
Noemí Del Toro-Cisneros, Erick Y Zuñiga-González, Adrián E Caballero-Islas, José A Geraldo-Murillo, Mauricio Arvizu-Hernández, Olynka Vega-Vega

The development of hemodialysis (HD) membranes has substantially advanced in the last decade. This has resulted in the manufacturing of medium cut-off membranes (MCO) whose internal architecture is based on greater pore size and a smaller diameter, thus promoting the clearance of particles of greater size as well as retrofiltration. Multiple studies have proven their efficacy in the clearance of uremic mid-sized molecules such as β2-microglobulin, free light chains, and some interleukins; this clearance is far superior with MCO membranes when compared with high-flux HD, and similar to that obtained with online hemodiafiltration. This review summarizes the results of the most relevant clinical studies of this membrane in terms of uremic toxin clearance, as well as the features of some clinical outcomes such as quality of life and hospitalizations.

在过去的十年里,血液透析(HD)膜的发展取得了长足的进步。这导致了介质截留膜(MCO)的制造,其内部结构基于更大的孔径和更小的直径,从而促进了更大尺寸颗粒的清除以及反滤。多项研究证明了它们对尿毒症中等大小分子如β2-微球蛋白、游离轻链和一些白细胞介素的清除作用;与高通量HD相比,MCO膜的这种清除率要高得多,并且与在线血液透析过滤获得的清除率相似。这篇综述总结了该膜在尿毒症毒素清除方面最相关的临床研究结果,以及一些临床结果的特征,如生活质量和住院治疗。
{"title":"Are medium cut-off membranes the future, or the promising reality for chronic hemodialysis patients?","authors":"Noemí Del Toro-Cisneros, Erick Y Zuñiga-González, Adrián E Caballero-Islas, José A Geraldo-Murillo, Mauricio Arvizu-Hernández, Olynka Vega-Vega","doi":"10.24875/RIC.23000213","DOIUrl":"10.24875/RIC.23000213","url":null,"abstract":"<p><p>The development of hemodialysis (HD) membranes has substantially advanced in the last decade. This has resulted in the manufacturing of medium cut-off membranes (MCO) whose internal architecture is based on greater pore size and a smaller diameter, thus promoting the clearance of particles of greater size as well as retrofiltration. Multiple studies have proven their efficacy in the clearance of uremic mid-sized molecules such as β2-microglobulin, free light chains, and some interleukins; this clearance is far superior with MCO membranes when compared with high-flux HD, and similar to that obtained with online hemodiafiltration. This review summarizes the results of the most relevant clinical studies of this membrane in terms of uremic toxin clearance, as well as the features of some clinical outcomes such as quality of life and hospitalizations.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":" ","pages":"289-299"},"PeriodicalIF":1.4,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71428374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pushing the boundaries of hemodialysis: innovations in membranes and sorbents. 突破血液透析的界限:膜和吸附剂的创新。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2023-12-18 DOI: 10.24875/RIC.23000223
Olynka Vega-Vega, Claudio Ronco, Amando J. Martínez-Rueda

Membranes and sorbents play a crucial role in extracorporeal blood purification therapies, which aim to remove harmful molecules and toxins from the blood. Over the years, advancements in hemodialysis (HD) membranes and sorbents have significantly enhanced their safety and effectiveness. This review article will summarize the latest breakthroughs in the development and clinical application of HD membranes and sorbents. We will commence with a concise examination of the mechanisms involved in solute transport across membranes and sorbents. Subsequently, we will explore the evolutionary path of HD membranes, from early cellophane membranes to high-flux membranes, including the development of high-cutoff membranes and the emergence of medium- cutoff membranes. We will discuss each type of HD membrane's advantages and limitations, highlighting the most promising advancements in novel biomaterials and biocompatibility, technologies, research in membrane performance, and their clinical applications. Furthermore, we will delve into the evolution and progress of sorbent technology, tracing its historical development, outlining its key characteristics, examining the mechanism involved in the adsorption process, and exploring its clinical application. This review aims to underscore the growth and future landscape of HD membranes and sorbents in extracorporeal blood purification techniques.

膜和吸附剂在体外血液净化疗法中发挥着至关重要的作用,该疗法旨在清除血液中的有害分子和毒素。多年来,血液透析(HD)膜和吸附剂的进步显著提高了其安全性和有效性。这篇综述文章将总结HD膜和吸附剂的开发和临床应用的最新突破。我们将从对溶质通过膜和吸附剂传输的机制进行简要的研究开始。随后,我们将探索HD膜的进化路径,从早期的玻璃纸膜到高通量膜,包括高截止膜的发展和中截止膜的出现。我们将讨论每种类型的HD膜的优势和局限性,重点介绍在新型生物材料和生物相容性、技术、膜性能研究及其临床应用方面最有前景的进展。此外,我们将深入研究吸附剂技术的演变和进展,追溯其历史发展,概述其关键特征,研究吸附过程中涉及的机制,并探索其临床应用。这篇综述旨在强调HD膜和吸附剂在体外血液净化技术中的发展和未来前景。
{"title":"Pushing the boundaries of hemodialysis: innovations in membranes and sorbents.","authors":"Olynka Vega-Vega, Claudio Ronco, Amando J. Martínez-Rueda","doi":"10.24875/RIC.23000223","DOIUrl":"10.24875/RIC.23000223","url":null,"abstract":"<p><p>Membranes and sorbents play a crucial role in extracorporeal blood purification therapies, which aim to remove harmful molecules and toxins from the blood. Over the years, advancements in hemodialysis (HD) membranes and sorbents have significantly enhanced their safety and effectiveness. This review article will summarize the latest breakthroughs in the development and clinical application of HD membranes and sorbents. We will commence with a concise examination of the mechanisms involved in solute transport across membranes and sorbents. Subsequently, we will explore the evolutionary path of HD membranes, from early cellophane membranes to high-flux membranes, including the development of high-cutoff membranes and the emergence of medium- cutoff membranes. We will discuss each type of HD membrane's advantages and limitations, highlighting the most promising advancements in novel biomaterials and biocompatibility, technologies, research in membrane performance, and their clinical applications. Furthermore, we will delve into the evolution and progress of sorbent technology, tracing its historical development, outlining its key characteristics, examining the mechanism involved in the adsorption process, and exploring its clinical application. This review aims to underscore the growth and future landscape of HD membranes and sorbents in extracorporeal blood purification techniques.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":" ","pages":"274-288"},"PeriodicalIF":1.4,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71428375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is generative artificial intelligence the next step toward a personalized hemodialysis? 生成人工智能是迈向个性化血液透析的下一步吗?
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2023-12-18 DOI: 10.24875/RIC.23000162
Miguel Hueso, Rafael Álvarez, David Marí, Vicent Ribas-Ripoll, Karim Lekadir, Alfredo Vellido

Artificial intelligence (AI) generative models driven by the integration of AI and natural language processing technologies, such as OpenAI's chatbot generative pre-trained transformer large language model (LLM), are receiving much public attention and have the potential to transform personalized medicine. Dialysis patients are highly dependent on technology and their treatment generates a challenging large volume of data that has to be analyzed for knowledge extraction. We argue that, by integrating the data acquired from hemodialysis treatments with the powerful conversational capabilities of LLMs, nephrologists could personalize treatments adapted to patients' lifestyles and preferences. We also argue that this new conversational AI integrated with a personalized patient-computer interface will enhance patients' engagement and self-care by providing them with a more personalized experience. However, generative AI models require continuous and accurate updates of data, and expert supervision and must address potential biases and limitations. Dialysis patients can also benefit from other new emerging technologies such as Digital Twins with which patients' care can also be addressed from a personalized medicine perspective. In this paper, we will revise LLMs potential strengths in terms of their contribution to personalized medicine, and, in particular, their potential impact, and limitations in nephrology. Nephrologists' collaboration with AI academia and companies, to develop algorithms and models that are more transparent, understandable, and trustworthy, will be crucial for the next generation of dialysis patients. The combination of technology, patient-specific data, and AI should contribute to create a more personalized and interactive dialysis process, improving patients' quality of life.

人工智能(AI)生成模型由人工智能和自然语言处理技术的集成驱动,如OpenAI的聊天机器人生成预训练转换器大语言模型(LLM),正受到公众的广泛关注,并有可能改变个性化医疗。透析患者高度依赖技术,他们的治疗产生了具有挑战性的大量数据,必须对这些数据进行分析以提取知识。我们认为,通过将从血液透析治疗中获得的数据与LLM强大的对话能力相结合,肾病学家可以根据患者的生活方式和偏好对治疗进行个性化。我们还认为,这种新的对话式人工智能与个性化的患者计算机界面相结合,将为患者提供更个性化的体验,从而增强患者的参与度和自我护理能力。然而,生成性人工智能模型需要持续准确的数据更新和专家监督,并且必须解决潜在的偏见和局限性。透析患者还可以受益于其他新兴技术,如数字双胞胎,通过这些技术,患者的护理也可以从个性化的医学角度来解决。在这篇论文中,我们将根据LLM对个性化医学的贡献,特别是其潜在影响和在肾病学中的局限性,对LLM的潜在优势进行修订。肾病学家与人工智能学术界和公司的合作,开发更透明、更可理解、更值得信赖的算法和模型,对下一代透析患者至关重要。技术、患者特定数据和人工智能的结合应该有助于创造一个更加个性化和互动的透析过程,提高患者的生活质量。
{"title":"Is generative artificial intelligence the next step toward a personalized hemodialysis?","authors":"Miguel Hueso, Rafael Álvarez, David Marí, Vicent Ribas-Ripoll, Karim Lekadir, Alfredo Vellido","doi":"10.24875/RIC.23000162","DOIUrl":"10.24875/RIC.23000162","url":null,"abstract":"<p><p>Artificial intelligence (AI) generative models driven by the integration of AI and natural language processing technologies, such as OpenAI's chatbot generative pre-trained transformer large language model (LLM), are receiving much public attention and have the potential to transform personalized medicine. Dialysis patients are highly dependent on technology and their treatment generates a challenging large volume of data that has to be analyzed for knowledge extraction. We argue that, by integrating the data acquired from hemodialysis treatments with the powerful conversational capabilities of LLMs, nephrologists could personalize treatments adapted to patients' lifestyles and preferences. We also argue that this new conversational AI integrated with a personalized patient-computer interface will enhance patients' engagement and self-care by providing them with a more personalized experience. However, generative AI models require continuous and accurate updates of data, and expert supervision and must address potential biases and limitations. Dialysis patients can also benefit from other new emerging technologies such as Digital Twins with which patients' care can also be addressed from a personalized medicine perspective. In this paper, we will revise LLMs potential strengths in terms of their contribution to personalized medicine, and, in particular, their potential impact, and limitations in nephrology. Nephrologists' collaboration with AI academia and companies, to develop algorithms and models that are more transparent, understandable, and trustworthy, will be crucial for the next generation of dialysis patients. The combination of technology, patient-specific data, and AI should contribute to create a more personalized and interactive dialysis process, improving patients' quality of life.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":" ","pages":"309-317"},"PeriodicalIF":1.4,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41153352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of remote monitoring in patients on automated peritoneal dialysis. 远程监测在自动腹膜透析患者中的应用。
IF 1.4 4区 医学 Q2 Medicine Pub Date : 2023-12-18 DOI: 10.24875/RIC.23000206
Ramón Paniagua, Marcela Ávila-Díaz, Miguel Á Trejo-Villeda, Alma S Bernal-Amador, Alfonso Ramos

Home hemodialysis (HD) and automated peritoneal dialysis (APD) have advantages over HD in hospitals or HD centers. Home therapies are generally less expensive and give patients greater mobility and freedom for work, school, family, and recreational activities. Technological advances have made it possible to complement APD with devices for remote monitoring (RM) of the patient. With them, objective information generated in the APD device is collected and sent to repositories "in the cloud" for analysis or at the time decided by the health team. With APD+RM, it is possible to monitor therapeutic compliance, effective dialysis time, ultrafiltration volumes, inflow and outflow patterns of dialysis fluid, and patient actions to respond to alarms that indicate deviations from the parameters set by the nephrologist. The results of APD+RM show good acceptance by the patient, nephrologists, and nurses, treatment adherence has improved, hospitalizations and technique failure have decreased, and some aspects of quality of life have improved. However, there is a lack of controlled clinical trials that reliably demonstrate lower mortality and comorbidity due to specific causes.

家庭血液透析(HD)和自动腹膜透析(APD)在医院或HD中心具有优于HD的优势。家庭疗法通常价格较低,并为患者提供更大的灵活性和工作、学校、家庭和娱乐活动的自由度。技术进步使得用患者的远程监测(RM)设备来补充APD成为可能。通过它们,APD设备中生成的客观信息被收集并发送到“云中”的存储库进行分析,或在健康团队决定的时间进行分析。使用APD+RM,可以监测治疗依从性、有效透析时间、超滤量、透析液的流入和流出模式,以及患者对指示偏离肾病学家设置的参数的警报的反应。APD+RM的结果显示患者、肾脏科医生和护士的良好接受度,治疗依从性得到改善,住院人数和技术故障减少,生活质量的某些方面得到改善。然而,缺乏可靠地证明特定原因导致的死亡率和合并症较低的对照临床试验。
{"title":"Utility of remote monitoring in patients on automated peritoneal dialysis.","authors":"Ramón Paniagua, Marcela Ávila-Díaz, Miguel Á Trejo-Villeda, Alma S Bernal-Amador, Alfonso Ramos","doi":"10.24875/RIC.23000206","DOIUrl":"10.24875/RIC.23000206","url":null,"abstract":"<p><p>Home hemodialysis (HD) and automated peritoneal dialysis (APD) have advantages over HD in hospitals or HD centers. Home therapies are generally less expensive and give patients greater mobility and freedom for work, school, family, and recreational activities. Technological advances have made it possible to complement APD with devices for remote monitoring (RM) of the patient. With them, objective information generated in the APD device is collected and sent to repositories \"in the cloud\" for analysis or at the time decided by the health team. With APD+RM, it is possible to monitor therapeutic compliance, effective dialysis time, ultrafiltration volumes, inflow and outflow patterns of dialysis fluid, and patient actions to respond to alarms that indicate deviations from the parameters set by the nephrologist. The results of APD+RM show good acceptance by the patient, nephrologists, and nurses, treatment adherence has improved, hospitalizations and technique failure have decreased, and some aspects of quality of life have improved. However, there is a lack of controlled clinical trials that reliably demonstrate lower mortality and comorbidity due to specific causes.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":" ","pages":"318-326"},"PeriodicalIF":1.4,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71428377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista De Investigacion Clinica-Clinical and Translational Investigation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1